# EDGAR Filing Document

**Accession Number:** 0001857190
**File Stem:** 0001104659-26-032163
**Filing Date:** 2026-3
**Character Count:** 31791
**Document Hash:** bb52aac9faa8e39a4a8a368a51974712
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-032163.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001104659-26-032163

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260319

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nyxoah SA
- **CENTRAL INDEX KEY:** 0001857190
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40552
- **FILM NUMBER:** 26775100

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** RUE EDOUARD BELIN 12
- **CITY:** MONT-SAINT-GUIBERT
- **PROVINCE COUNTRY:** C9
- **ZIP:** 1435
- **BUSINESS PHONE:** 3210222355

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** RUE EDOUARD BELIN 12
- **CITY:** MONT-SAINT-GUIBERT
- **PROVINCE COUNTRY:** C9
- **ZIP:** 1435

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

Commission File Number: **001-40552**

**NYXOAH SA**

(Translation of registrant's name into English)

**Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**Nyxoah SA**

On March 19, 2026, Nyxoah SA (the "Company") issued a press release announcing its financial and operating results for the year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

Additionally, on February 25, 2026, February 27, 2026 and March 13, 2026, the Company issued releases, copies of which are attached hereto as exhibits 99.2, 99.3 and 99.4.

*The information in the attached Exhibit 99.1, 99.2, 99.3 and 99.4 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.*

**<u>Exhibits</u>**

---

| | |
|:---|:---|
| [<u>99.1</u>](tm269369d1_ex99-1.htm) | [<u>Press Release, dated March 19, 2026</u>](tm269369d1_ex99-1.htm) |
| [<u>99.2</u>](tm269369d1_ex99-2.htm) | [<u>Press Release, dated February 25, 2026</u>](tm269369d1_ex99-2.htm) |
| [<u>99.3</u>](tm269369d1_ex99-3.htm) | [<u>Press Release, dated February 27, 2026</u>](tm269369d1_ex99-3.htm) |
| [<u>99.4</u>](tm269369d1_ex99-4.htm) | [<u>Press Release, dated March 13, 2026</u>](tm269369d1_ex99-4.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NYXOAH SA** | **NYXOAH SA** |
| Date: March 19, 2026 | By: | /s/ John Landry |
|  | Name: | John Landry |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**REGULATED INFORMATION**

![](tm269369d1_ex99-1img001.jpg)

**Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results**

*U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales* 

*Foundation Established to Drive Significant Growth in 2026*

**Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)** ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025.

**Recent Financial and Operating Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;· Fourth
 quarter gross revenue of €6.3 million, resulting in net revenue of €5.6 million,
 which represents 347% year-over-year growth, driven by the first full quarter of US commercialization

&nbsp;&nbsp;&nbsp;&nbsp;· Full
 year gross revenue of €11.0 million, resulting in net revenue of €10.0 million,
 which represents 122% year-over-year growth

&nbsp;&nbsp;&nbsp;&nbsp;· Fourth
 quarter gross margin of approximately 64%

&nbsp;&nbsp;&nbsp;&nbsp;· Cash,
 cash equivalents and financial assets of €48.0 million at December 31, 2025

&nbsp;&nbsp;&nbsp;&nbsp;· 145
 surgeons trained and 57 accounts activated in the U.S. since commercial launch in August 2025

&nbsp;&nbsp;&nbsp;&nbsp;· Genio
 system consistently reimbursed by both commercial payors and Medicare to date

&nbsp;&nbsp;&nbsp;&nbsp;· Expanding
 manufacturing footprint to support global growth

"The fourth quarter marked our first full quarter of U.S. commercialization, and we are very pleased with the strong momentum we generated which led to us exceeding our revenue expectations for the quarter," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "The feedback from surgeons and their patients has been positive and these procedures have been consistently reimbursed by major commercial payors and Medicare to date. We are excited about the opportunity in front of us and feel confident we will deliver significant growth going forward."

![](tm269369d1_ex99-1img001.jpg)

**U.S. Commercial Launch**

The fourth quarter represented the first full quarter of commercial activity in the United States following FDA approval of the Genio® system in August 2025. The Company is executing its focused two-pronged launch strategy targeting high-volume hypoglossal nerve stimulation implanting centers while educating referral networks with sleep physicians managing moderate to severe OSA patients.

As of December 31, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;· 145
 surgeons had been trained on the Genio system

&nbsp;&nbsp;&nbsp;&nbsp;· 57
 U.S. accounts had been activated

&nbsp;&nbsp;&nbsp;&nbsp;· Genio
 has been consistently reimbursed by many large commercial payors and Medicare to date

![](tm269369d1_ex99-1img001.jpg)

**CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)** 

**(in thousands EUR)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For year ended <br> December 31** | **For year ended <br> December 31** | **For year ended <br> December 31** | **For year ended <br> December 31** | **For the three months<br> ended December 31** | **For the three months<br> ended December 31** | **For the three months<br> ended December 31** | **For the three months<br> ended December 31** |
|  | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Revenue |  | 10 020 |  | 4 521 |  | 5 644 |  | 1 263 |
| Cost of goods sold |  | (3 694) |  | (1 552) |  | (2 019) |  | (335) |
| **Gross profit** | **€** | **6326** | **€** | **2969** | **€** | **3 625** | **€** | **928** |
| Research and Development Expense |  | (42 824) |  | (34325) |  | (10865) |  | (11752) |
| Selling, General and Administrative Expense |  | (48261) |  | (28461) |  | (12496) |  | (8065) |
| Other income |  | 1274 |  | 1008 |  | 1108 |  | 578 |
| **Operating loss for the period** | **€** | **(83485)** | **€** | **(58809)** | **€** | **(18628)** | **€** | **(18311)** |
| Financial income |  | 5 928 |  | 7 447 |  | (633) |  | 2 832 |
| Financial expense |  | (11 519) |  | (5 070) |  | (3 357) |  | (410) |
| **Loss for the period before taxes** | **€** | **(89 076)** | **€** | **(56 432)** | **€** | **(22 618)** | **€** | **(15 069)** |
| Income taxes |  | (1 009) |  | (2 804) |  | (895) |  | (2 080) |
| **Loss for the period** | **€** | **(90 085)** | **€** | **(59 236)** | **€** | **(23 513)** | **€** | **(17 149)** |
| **Loss attributable to equity holders** | **€** | **(90 085)** | **€** | **(59 236)** | **€** | **(23 513)** | **€** | **(17 149)** |
| **Other comprehensive loss** |  |  |  |  |  |  |  |  |
| **Items that may be subsequently reclassified to profit or loss (net of tax)** |  |  |  |  |  |  |  |  |
| **Remeasurements of post-employment benefit obligations, net of tax** |  | (18) |  | 11 |  | (18) |  | (11) |
| Currency translation differences |  | 228 |  | 766 |  | 31 |  | (987) |
| **Total comprehensive loss for the year, net of tax** |  | **210** |  | **777** |  | **13** |  | (976) |
| **Loss attributable to equity holders** | **€** | **(89875)** | **€** | **(58459)** | **€** | **(23500)** | **€** | **(16151)** |
| Basic Loss Per Share (in EUR) | € | (2.364) | € | (1.809) | € | (0.586) | € | (0.463) |
| Diluted Loss Per Share (in EUR) | € | (2.364) | € | (1.809) | € | (0.586) | € | (0.463) |

---

![](tm269369d1_ex99-1img001.jpg)

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited)**

**(in thousands EUR)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As at December 31** | **As at December 31** | **As at December 31** | **As at December 31** |
|  | **2025** | **2025** | **2024** | **2024** |
| **ASSETS** |  |  |  |  |
| **Non-current assets** |  |  |  |  |
| Property, plant and equipment |  | 4052 |  | 4753 |
| Intangible assets |  | 50108 |  | 50381 |
| Right of use assets |  | 1293 |  | 3496 |
| Deferred tax asset |  | 87 |  | 76 |
| Other long-term receivables |  | 1718 |  | 1617 |
|  | **€** | **57258** | **€** | **60323** |
| **Current assets** |  |  |  |  |
| Inventory |  | 4660 |  | 4716 |
| Trade receivables |  | 5254 |  | 3382 |
| Contract assets |  | 261 |  |  |
| Other receivables |  | 2209 |  | 2774 |
| Other current assets |  | 828 |  | 1656 |
| Financial assets |  | 18000 |  | 51369 |
| Cash and cash equivalents |  | 30001 |  | 34186 |
|  | **€** | **61213** | **€** | **98083** |
| &nbsp;&nbsp;&nbsp;**Total assets** | **€** | **118471** | **€** | **158406** |
| **EQUITY AND LIABILITIES** |  |  |  |  |
| **Share capital and reserves** |  |  |  |  |
| Share capital |  | 6505 |  | 6430 |
| Share premium |  | 335134 |  | 314345 |
| Share-based payment reserve |  | 12395 |  | 9300 |
| Other comprehensive income |  | 1124 |  | 914 |
| Retained loss |  | (306 029) |  | (217735) |
| &nbsp;&nbsp;&nbsp;**Total equity attributable to shareholders** | **€** | **49129** | **€** | **113254** |
| **LIABILITIES** |  |  |  |  |
| **Non-current liabilities** |  |  |  |  |
| Financial debt |  | 17670 |  | 18725 |
| Lease liability |  | 637 |  | 2562 |
| Provisions |  | 1396 |  | 1000 |
| Deferred tax liability |  |  |  | 19 |
| Contract liability |  | 681 |  | 472 |
| Other liability |  | - |  | 845 |
|  | **€** | **20384** | **€** | **23623** |
| **Current liabilities** |  |  |  |  |
| Financial debt |  | 22990 |  | 248 |
| Lease liability |  | 779 |  | 1118 |
| Trade payables |  | 13727 |  | 9505 |
| Current tax liability |  | 3939 |  | 4317 |
| Contract liability |  | 894 |  | 117 |
| Other liability |  | 6629 |  | 6224 |
|  | **€** | **48958** | **€** | **21529** |
| &nbsp;&nbsp;&nbsp;**Total liabilities** | **€** | **69342** | **€** | **45152** |
| &nbsp;&nbsp;&nbsp;**Total equity and liabilities** | **€** | **118471** | **€** | **158406** |

---

![](tm269369d1_ex99-1img001.jpg)

**Revenue**

Gross revenue for the fourth quarter of 2025 was €6.3 million before €0.7 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €5.6 million compared to €1.3 million in the fourth quarter of 2024.

For the full year 2025, gross revenue was €11.0 million before €1.0 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €10.0 million compared to €4.5 million in 2024. The increase in net revenue was primarily due to the launch of U.S. commercialization activities beginning in August 2025, post PMA approval.

**Cost of Goods Sold**

Cost of goods sold was €2.0 million for the three months ended December 31, 2025, resulting in gross profit of €3.6 million and a gross margin of approximately 64%, compared to cost of goods sold of €0.3 million and gross margin of 73% in the fourth quarter of 2024.

For the full year ended December 31, 2025, cost of goods sold was €3.7 million, resulting in gross profit of €6.3 million and a gross margin of approximately 63%, compared to cost of goods sold of €1.6 million and gross margin of 66% in 2024. The increase in cost of goods sold was due to a higher volume of Genio systems sold in 2025 while gross margin decreased slightly on a year over year basis due to initial ramp-up operational activities in advance of the Company's U.S. commercial launch.

**Research and Development**

Research and development expenses were €10.9 million for the fourth quarter of 2025, compared to €11.8 million for the fourth quarter of 2024.

For the full year ended December 31, 2025, research and development expenses were €42.8 million, compared to €34.3 million in 2024. The increase in research and development expenses was primarily driven by continued clinical expansion initiatives and ongoing product development activities.

**Selling, General and Administrative**

Selling, general and administrative expenses were €12.5 million for the fourth quarter of 2025, compared to €8.1 million for the fourth quarter of 2024.

For the full year ended December 31, 2025, selling, general and administrative expenses were €48.3 million, compared to €28.5 million in 2024. The increase was primarily driven by the build-out of the Company's U.S. commercial organization, including sales, marketing, and market access functions.

**Operating Loss**

Total operating loss for the fourth quarter of 2025 was €18.6 million, compared to €18.3 million in the fourth quarter of 2024.

![](tm269369d1_ex99-1img001.jpg)

For the full year ended December 31, 2025, total operating loss was €83.5 million, compared to €58.8 million in 2024. The increase reflects the planned acceleration of U.S. commercialization investments, continued clinical expansion initiatives and ongoing product development activities.

**Cash Position**

Cash, cash equivalents and financial assets amounted to €48.0 million at December 31, 2025.

**Revenue Guidance**

&nbsp;&nbsp;&nbsp;&nbsp;· We
 expect U.S. net revenue for the first quarter of 2026 to grow by approximately 25% over the
 fourth quarter of 2025 and expect net revenue for the second quarter of 2026 to grow by approximately
 25% over the first quarter of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;· International
 revenue is expected to follow a typical seasonal pattern.

**Annual Report 2025**

Nyxoah is currently finalizing the financial statements for the year ended December 31, 2025. The Company's independent auditor has confirmed that their audit procedures, which have been substantially completed, have not revealed any material adjustments which would have to be made to the accounting information included in this press release. The complete consolidated financial statements for the year ended December 31, 2025 as well as the complete audit report related to the audit of the consolidated financial statements will be included in the 2025 Annual Report which the Company aims to publish on or around March 26, 2026. When published, the Nyxoah Annual Report for the financial year 2025 will be available on the investor page of Nyxoah's website (<u>https://investors.nyxoah.com/financials</u>).

**Conference call and webcast presentation**

Company management will host a conference call to discuss financial results on Thursday, March 19, 2026, beginning at 9:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: <u>Nyxoah's Q4 and FY 2025 Earnings Call Webcast</u>. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: <u>Nyxoah's Q4 and FY 2025 Earnings Call Q&A Link</u>. required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

**About Nyxoah**

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah's lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

![](tm269369d1_ex99-1img001.jpg)

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit <u>http://www.nyxoah.com/.</u>

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

**Forward-looking statements**

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or management's current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue results and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on March 20, 2025, and any subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

![](tm269369d1_ex99-1img001.jpg)

**Contacts:**

**Nyxoah** 

John Landry, CFO

<u>IR@nyxoah.com</u>

Rémi Renard

Head of Investor Relations & Corporate Communication

<u>IR@nyxoah.com</u>

## Exhibit 99.2

**Exhibit 99.2**

![](tm269369d1_ex99-2img001.jpg)

**Information on the total number of voting rights and shares**

February 25, 2026

**REGULATED INFORMATION**

**Information on the total number of voting rights and shares**

**Mont-Saint-Guibert (Belgium), February 25, 2026, 10:30 pm CET / 4:30 pm ET –** In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Share capital: EUR 6,511,048.19

· Total number of securities carrying voting rights: 43,662,403
(all ordinary shares)

· Total number of voting rights (= denominator): 43,662,403 (all
relating to ordinary shares)

· Number of rights to subscribe to securities carrying voting
rights not yet issued: 3,416,319 (all granted subscription rights; this number excludes 462,677 subscription rights that were issued
but not yet granted)

· Total number of convertible bonds: 225 convertible bonds with
a nominal value of EUR 91,500 per bond

· Total number of voting rights that can be obtained in case of
conversion of all 225 convertible bonds at the current conversion price of EUR 5.00 per share: 4,117,500

\*

\* \*

**Contact:** 

**Nyxoah** 

John Landry, CFO

IR@nyxoah.com

**Attachment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· <u>2026 02 25 - Press release - Number of shares (ENG)</u>

## Exhibit 99.3

**Exhibit 99.3**

![](tm269369d1_ex99-3img001.jpg)

**Publication relating to transparency notifications**

February 27, 2026

**REGULATED INFORMATION**

**Publication relating to transparency notifications**

**Mont-Saint-Guibert (Belgium), February 27, 2026, 10:30 pm CET / 4:30 pm ET –** In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

**<u>Robert Taub / BMI Estate</u>**

On February 26, 2026, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate, following the passive crossing of a threshold. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 9.99% of the total number of voting rights on February 20,

2026 (43,662,403).

The notification dated February 26, 2026 contains the following information:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Reason for the notification: passive crossing of a threshold

· Notification by: a parent undertaking or a controlling person

· Persons subject to the notification requirement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Robert Taub

· BMI Estate (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Date on which the threshold was crossed: February 20, 2026

· Threshold that is crossed: 10%

· Denominator: 43,662,403

· Notified details:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **A) Voting rights** | | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| | **Previous**<br>**notification**<br>**# of voting rights** | **# of voting rights** | **# of voting rights** | **% of voting rights** | **% of voting rights** |
| <br>**Holders of voting rights** | | **Linked to**<br>**securities** | **Not linked to the**<br>**securities** | **Linked to**<br>**securities** | **Not linked to**<br>**the securities** |
| Robert Taub | 2712510 | 2712510 |  | 6.21% |  |
| BMI Estate | 567484 | 567484 |  | 1.30% |  |
| Robelga SRL | 1030806 | 1030806 |  | 2.36% |  |
| Subtotal | 4310800 | 4310800 |  | 9.87% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL** |  | **4310800** | **0** | **9.87%** | **0.00%** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **B) Equivalent financial instruments** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| <br>**Holders of equivalent financial instruments** |<br><br>**Type of financial**<br>**instrument** | <br>**Expiration date** | **# of voting**<br>**rights that may**<br>**be acquired if**<br>**the instrument**<br>**is exercised** |<br><br>**% of voting**<br>**rights** |<br><br>**Settlement** |
| Robert Taub | Warrants | 08/06/2027 | 25000 | 0.06% | cash |
| Robert Taub | Warrants | 14/06/2028 | 25000 | 0.06% | cash |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL** |  |  | **50000** | **0.11%** |  |

---

 

---

| | | |
|:---|:---|:---|
| **TOTAL (A & B)** | **# of voting rights** | **% of voting rights** |
|  | **4360800** | **9.99%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· <u>Full chain of controlled undertakings through which the holding is effectively held</u>: Robelga SRL is 100% owned
 by BMI Estate (a partnership (*société simple*) without legal personality).
 Robert Taub has 100% usufruct and Robert Taub's children have 100% bare ownership of
 BMI Estate.

\*

\* \*

**Contact:** 

**Nyxoah** 

John Landry, CFO

IR@nyxoah.com

**Attachment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· <u>2026</u> <u>02 27 PR Transparency notification (Robert Taub) (ENG)</u>

## Exhibit 99.4

**Exhibit 99.4**

![](tm269369d1_ex99-4img001.jpg)

**Publication relating to transparency notification**

March 13, 2026

**REGULATED INFORMATION**

**Publication relating to transparency notification**

**Mont-Saint-Guibert (Belgium), March 13, 2026, 10:30 pm CET / 5:30 pm ET –** In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

**<u>BNP Paribas Asset Management</u>**

On March 11, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas

Asset Management Europe SAS holds 1,307,817 voting rights, representing 3.00% of the total number of voting rights on March 9, 2026 (43,662,403).

The notification dated March 11, 2026 contains the following information:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Reason for the notification:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Acquisition or disposal of voting securities or voting rights

· Downward crossing of the lowest threshold

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Notification by: a parent undertaking or a controlling person

· Person subject to the notification requirement: BNP Paribas Asset Management SA (with address at SA 47000-75318 Paris cedex 09-France)

· Date on which the threshold was crossed: March 9, 2026

· Threshold that is crossed: 3%

· Denominator: 43,662,403

· Notified details:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **A) Voting rights** | | | | | |
| | | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| | **Previous**<br>**notification**<br>**# of voting rights** | **# of voting rights** | **# of voting rights** | **% of voting rights** | **% of voting rights** |
| <br>**Holders of voting rights** | | **Linked to**<br>**securities** | **Not linked to the**<br>**securities** | **Linked to**<br>**securities** | **Not linked to**<br>**the securities** |
| BNP Paribas Asset | 0 | 0 |  | 0.00% |  |
| Management Holding |  |  |  |  |  |
| BNP Paribas Asset |  |  |  |  |  |
| Management Europe | 1409791 | 1307817 |  | 3.00% |  |
| SAS |  |  |  |  |  |
| Subtotal | 1409791 | 1307817 |  | 3.00% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL** |  | **1307817** | **0** | **3.00%** | **0.00%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· <u>Full chain of controlled undertakings through which the holding is effectively held</u>: The subsidiary BNP Paribas
 Asset Management Europe SAS is controlled by the parent company BNP Paribas Asset Management
 Holding. This parent company is itself controlled by the parent company BNP Paribas SA, which
 benefits from an exemption from aggregating its shareholdings with those of its subsidiaries
 investment companies, in accordance with article 21, paragraph 2 of the Royal Decree of February
 14, 2008 on the disclosure of major shareholdings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· <u>Additional information</u>:
 The subsidiary BNP Paribas Asset Management Europe SAS is an investment company that exercises
 voting rights on a discretionary basis in the absence of specific instructions.

\*

\* \*

**Contact:** 

**Nyxoah** 

John Landry, CFO

IR@nyxoah.com

**Attachment**

&nbsp;&nbsp;&nbsp;&nbsp;· <u>2026 03 13 PR Transparency notification (BNP Paribas) (ENG)</u>